NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 168 filers reported holding NEKTAR THERAPEUTICS in Q3 2015. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,709 | +3.5% | 23,010 | 0.0% | 0.00% | – |
Q2 2023 | $13,240 | -31.4% | 23,010 | -16.2% | 0.00% | – |
Q1 2023 | $19,296 | -62.9% | 27,448 | +19.3% | 0.00% | – |
Q4 2022 | $52,000 | -10.3% | 23,010 | +27.8% | 0.00% | – |
Q3 2022 | $58,000 | -14.7% | 18,010 | 0.0% | 0.00% | – |
Q2 2022 | $68,000 | -29.9% | 18,010 | 0.0% | 0.00% | – |
Q1 2022 | $97,000 | -60.1% | 18,010 | 0.0% | 0.00% | – |
Q4 2021 | $243,000 | -24.8% | 18,010 | -0.2% | 0.00% | -100.0% |
Q3 2021 | $323,000 | -21.2% | 18,051 | -25.3% | 0.00% | 0.0% |
Q2 2021 | $410,000 | -14.0% | 24,158 | -0.0% | 0.00% | 0.0% |
Q1 2021 | $477,000 | +11.7% | 24,161 | -4.7% | 0.00% | 0.0% |
Q4 2020 | $427,000 | +2.9% | 25,352 | +1.0% | 0.00% | 0.0% |
Q3 2020 | $415,000 | -13.5% | 25,109 | +20.8% | 0.00% | 0.0% |
Q2 2020 | $480,000 | +44.6% | 20,788 | +10.8% | 0.00% | 0.0% |
Q1 2020 | $332,000 | -9.8% | 18,754 | +9.7% | 0.00% | 0.0% |
Q4 2019 | $368,000 | +42.1% | 17,101 | +137.6% | 0.00% | 0.0% |
Q2 2019 | $259,000 | +15.6% | 7,198 | +9.6% | 0.00% | 0.0% |
Q1 2019 | $224,000 | -92.0% | 6,565 | -88.3% | 0.00% | -90.0% |
Q4 2018 | $2,810,000 | +33.9% | 56,014 | +62.7% | 0.01% | +25.0% |
Q3 2018 | $2,099,000 | -32.2% | 34,423 | -45.7% | 0.01% | -27.3% |
Q2 2018 | $3,097,000 | -70.0% | 63,435 | -34.8% | 0.01% | -72.5% |
Q1 2018 | $10,331,000 | +43.6% | 97,230 | -19.3% | 0.04% | +60.0% |
Q4 2017 | $7,194,000 | +25.8% | 120,462 | -49.5% | 0.02% | +25.0% |
Q3 2017 | $5,720,000 | -8.4% | 238,330 | -25.4% | 0.02% | -20.0% |
Q2 2017 | $6,243,000 | +27.8% | 319,353 | +53.4% | 0.02% | +19.0% |
Q1 2017 | $4,886,000 | +56.9% | 208,168 | -18.0% | 0.02% | +40.0% |
Q4 2016 | $3,114,000 | +2452.5% | 253,823 | +3464.9% | 0.02% | +1400.0% |
Q3 2016 | $122,000 | -85.1% | 7,120 | -87.6% | 0.00% | -80.0% |
Q2 2016 | $818,000 | +37.0% | 57,508 | +32.5% | 0.01% | +25.0% |
Q1 2016 | $597,000 | -23.0% | 43,414 | -5.6% | 0.00% | -20.0% |
Q4 2015 | $775,000 | -33.2% | 45,986 | -56.6% | 0.01% | -54.5% |
Q3 2015 | $1,161,000 | +101.9% | 105,889 | +130.3% | 0.01% | +120.0% |
Q2 2015 | $575,000 | +13.6% | 45,986 | 0.0% | 0.01% | +25.0% |
Q1 2015 | $506,000 | – | 45,986 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |